Titan Medical Reports Voting Results from Annual and Special Meeting of Shareholders
October 01 2020 - 7:00AM
Business Wire
Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD)
(Nasdaq: TMDI), a medical device company focused on the design
and development of robotic surgical technologies, announced the
voting results from the Company’s Annual and Special Meeting of its
Shareholders held on Wednesday, September 30, 2020.
All of management’s nominees for election were duly elected as
directors of the Company by the shareholders present or represented
by proxy at the meeting. A total of 52,225,437 of the 81,524,320
common shares outstanding, or 64.06%, were voted at the meeting.
The results of the vote were reported to the meeting by
Computershare, which acted as scrutineer at the meeting, as
follows:
Votes For
%
Votes Withheld
%
Paul Cataford
14,828,068
61.49
9,285,489
38.51
Anthony Giovinazzo
13,605,844
56.42
10,507,712
43.58
David McNally
12,456,944
51.66
11,656,612
48.34
Stephen Randall
13,798,722
57.22
10,314,627
42.78
Cary Vance
13,847,172
57.42
10,266,361
42.58
The appointment of BDO Canada LLP as independent auditors of the
Company was approved by shareholders (with 33,803,053 votes for and
18,421,383 votes withheld) in respect of the motion.
The shareholder proposal for an amendment to the Company’s stock
option plan was rejected with 9,557,582 votes for and 14,555,974
votes against. The shareholder proposal to authorize the
consolidation of the outstanding common shares of the Company was
rejected with 20,125,386 votes for and 32,099,050 votes
against.
The video shown during the Annual and Special Meeting featuring
progress at the Company’s research and development facility located
in Chapel Hill, North Carolina, has been posted to the Company’s
website.
About Titan
Titan Medical Inc. is focused on robotic-assisted technologies
for application in minimally invasive surgery (“MIS”). Enos, by
Titan Medical, is being developed to become the new standard of
care in robotic single access surgery, and comprises a
surgeon-controlled patient cart that includes a dual-view camera
system with 3D and 2D high-definition vision systems and
multi-articulating instruments for performing MIS procedures, and a
surgeon workstation that provides an ergonomic interface to the MIS
procedure performed through the patient cart. With the Enos system,
Titan intends to initially pursue gynecologic surgical
indications.
For more information, visit www.titanmedicalinc.com.
Forward-Looking Statements
This news release contains “forward-looking statements” within
the meaning of applicable Canadian and U.S. securities laws. Such
statements reflect the current expectations of management of the
Company’s future growth, results of operations, performance and
business prospects and opportunities. Wherever possible, words such
as “may”, “would”, “could”, “will”, “anticipate”, “believe”,
“plan”, “expect”, “intend”, “estimate”, “potential for” and similar
expressions have been used to identify these forward-looking
statements. These statements reflect management’s current beliefs
with respect to future events and are based on information
currently available to management. Forward-looking statements
involve significant risks, uncertainties and assumptions. Many
factors could cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements that may be expressed or implied by
such forward-looking statements, including, without limitation,
those listed in the “Risk Factors” section of the Company’s Annual
Report on Form 20F dated March 30, 2020 (which may be viewed at
www.sedar.com and at www.sec.gov). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. These factors should be considered
carefully, and prospective investors should not place undue
reliance on the forward-looking statements. Although the
forward-looking statements contained in the news release are based
upon what management currently believes to be reasonable
assumptions, the Company cannot assure prospective investors that
actual results, performance or achievements will be consistent with
these forward-looking statements. Except as required by law, the
Company expressly disclaims any intention or obligation to update
or revise any forward-looking statements whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201001005343/en/
Monique L. Delorme Chief Financial Officer +1-416-548-7522
info@titanmedicalinc.com
Titan Medical (TSX:TMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Medical (TSX:TMD)
Historical Stock Chart
From Apr 2023 to Apr 2024